Media & Resources

Scientific Publications

The importance of partnerships in accelerating HIV vaccine research and development

Press Releases

IAVI and the Biomedical Advanced Research and Development Authority partner to advance filovirus vaccine candidates

October 27, 2021

NEW YORK – OCTOBER 27, 2021 – IAVI announced today the award of up to US$126 million from the Biomedical Advanced Research and Development Authority (BARDA) at the U.S. Department of Health and Human Services to develop two recombinant vesicular stomatitis virus (rVSV)-vectored filovirus vaccine candidates. This award supports preclinical activities and includes options for…

Features

TB survivors from G20 countries call upon their leaders to invest $1 billion per year to develop new TB vaccines

October 20, 2021

The call is endorsed by a global coalition advocating for a fully funded and resourced TB vaccine pipeline by 2023.

Features

Vaccines Security in Africa – Which Way Next?

October 18, 2021

IAVI and African Vaccine Manufacturing Initiative host virtual forum.

Scientific Publications

Safety pharmacokinetics and antiviral activity of PGT121 a broadly neutralizing monoclonal antibody against HIV 1 a randomized placebo controlled phase 1 clinical trial

Scientific Publications

Increased Frequency of Inter Subtype HIV 1 Recombinants Identified by Near Full Length Virus Sequencing in Rwandan Acute Transmission Cohorts

Features

IAVI applauds Biden Administration’s intent to nominate John Nkengasong as head of PEPFAR

September 30, 2021

Nkengasong was a founding leader of PEPFAR and has served on IAVI’s board since 2018.

Scientific Publications

Structurally related but genetically unrelated antibody lineages converge on an immunodominant HIV 1 Env neutralizing determinant following trimer immunization

1…58 596061 62…235 of 235

Media & Resources

Filter by

Type

Health area

Location

Topic

Year

Journal

Publication

Fact sheet & publication type

The importance of partnerships in accelerating HIV vaccine research and development

IAVI and the Biomedical Advanced Research and Development Authority partner to advance filovirus vaccine candidates

TB survivors from G20 countries call upon their leaders to invest $1 billion per year to develop new TB vaccines

Vaccines Security in Africa – Which Way Next?

Safety pharmacokinetics and antiviral activity of PGT121 a broadly neutralizing monoclonal antibody against HIV 1 a randomized placebo controlled phase 1 clinical trial

Increased Frequency of Inter Subtype HIV 1 Recombinants Identified by Near Full Length Virus Sequencing in Rwandan Acute Transmission Cohorts

IAVI applauds Biden Administration’s intent to nominate John Nkengasong as head of PEPFAR

Structurally related but genetically unrelated antibody lineages converge on an immunodominant HIV 1 Env neutralizing determinant following trimer immunization

Media & Resources

Filter by

Type

Health area

Location

Topic

Year

Journal

Publication

Fact sheet & publication type

The importance of partnerships in accelerating HIV vaccine research and development

IAVI and the Biomedical Advanced Research and Development Authority partner to advance filovirus vaccine candidates

TB survivors from G20 countries call upon their leaders to invest $1 billion per year to develop new TB vaccines

Vaccines Security in Africa – Which Way Next?

Safety pharmacokinetics and antiviral activity of PGT121 a broadly neutralizing monoclonal antibody against HIV 1 a randomized placebo controlled phase 1 clinical trial

Increased Frequency of Inter Subtype HIV 1 Recombinants Identified by Near Full Length Virus Sequencing in Rwandan Acute Transmission Cohorts

IAVI applauds Biden Administration’s intent to nominate John Nkengasong as head of PEPFAR

Structurally related but genetically unrelated antibody lineages converge on an immunodominant HIV 1 Env neutralizing determinant following trimer immunization

Subscription Type